Bisphosphonate (bone resorption inhibitor)
Pregnancy: Not applicable (post-menopausal use; avoid in women of childbearing age).
Alendronic Acid (Alendronate)
Brand names: Fosamax, Binosto
Adult dose
Dose: Osteoporosis: 70 mg once weekly; Paget's disease: 40 mg daily for 6 months
Route: Oral (strict administration requirements — see notes)
Frequency: Once weekly (osteoporosis)
Max: 70 mg/week (osteoporosis)
Osteoporosis prevention/treatment: 70 mg once weekly. Take in the morning after overnight fast with full glass of water (200 mL minimum). Remain upright for at least 30 min after and before eating/drinking/other medication. Do not lie down. Take calcium and Vit D supplements (2 hours apart from alendronate).
Paediatric dose
Route: Not applicable
Frequency: Not licensed in children
Max: Not applicable
Not licensed for osteoporosis in children. Pamidronate IV used by specialist for childhood osteoporosis (OI).
Dose adjustments
Renal
Avoid if eGFR <35 mL/min (accumulation; no clinical data).
Hepatic
No dose adjustment required.
Clinical pearls
- Administration technique critical — oesophageal ulceration is preventable with correct technique
- Drug holiday: review at 5 years — patients with T-score >-2.5 may safely stop
- Dental care: before starting, dental review and any extractions completed (ONJ risk reduced)
- Atypical femoral fracture: pain in thigh/groin — X-ray, consider drug holiday
- Calcium 1000 mg/day and Vitamin D 800 IU/day supplementation essential alongside
Contraindications
- Oesophageal abnormalities (stricture, achalasia — unable to sit upright)
- Hypocalcaemia (treat before starting)
- Unable to sit or stand upright for 30 min
- eGFR <35 mL/min
Side effects
- Oesophageal irritation and ulceration (if administration instructions not followed)
- Abdominal pain and dyspepsia
- Osteonecrosis of the jaw (rare — especially with IV bisphosphonates; risk with oral after >3 years)
- Atypical femoral fractures (long-term use >5 years)
- Hypocalcaemia (transient)
Interactions
- Calcium, antacids — chelate alendronate; take 2 hours apart
- NSAIDs — increased risk of GI irritation
- Aspirin — increased GI effects
Monitoring
- DEXA at 2–5 years
- Serum calcium and Vit D
- Renal function annually
- Jaw pain
Reference: BNFc; BNF; NICE CG146 Osteoporosis; NOGG Guidelines 2021. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- Corrected Reticulocyte Count / Reticulocyte Production Index · Anaemia
- Tumor Lysis Syndrome Risk (Cairo-Bishop) · Oncological Emergency
Pathways
- Falls Assessment in Older Adults · NICE CG161 2013
- Delirium Outside ICU · NICE CG103
- Comprehensive Geriatric Assessment (CGA) · BGS / NICE
- Delirium Assessment and Management · NICE CG103 2010
- Frailty Recognition and Management · BGS Frailty Framework / NHS NHSE
- Polypharmacy and Medicines Optimisation · STOPP/START v2 2014 / NICE NG5